Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Dowsett M, Ellis MJ, Dixon JM, Gluz O, Robertson J, Kates R, Suman VJ, Turnbull AK, Nitz U, Christgen M, Kreipe H, Kuemmel S, Bliss JM, Barry P, Johnston SR, Jacobs SA, Ma CX, Smith IE, Harbeck N. Dowsett M, et al. Among authors: dixon jm. NPJ Breast Cancer. 2020 Jun 8;6:21. doi: 10.1038/s41523-020-0168-9. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32550266 Free PMC article.
Breast cancer: non-metastatic.
Dixon JM, Gregory K, Johnston S, Rodger A. Dixon JM, et al. Clin Evid. 2002 Jun;(7):1603-30. Clin Evid. 2002. PMID: 12230775 Updated. Review. No abstract available.
Breast cancer: non-metastatic.
Dixon JM, Gregory K, Johnston S, Rodger A. Dixon JM, et al. Clin Evid. 2002 Dec;(8):1811-39. Clin Evid. 2002. PMID: 12603971 Updated. Review. No abstract available.
Breast cancer (non-metastatic).
Dixon JM, Gregory K, Johnston S, Rodger A. Dixon JM, et al. Clin Evid. 2003 Jun;(9):1940-70. Clin Evid. 2003. PMID: 12967459 Updated. Review. No abstract available.
Breast cancer (non-metastatic).
Dixon JM, Gregory K, Johnston S, Rodger A. Dixon JM, et al. Clin Evid. 2004 Jun;(11):2300-33. Clin Evid. 2004. PMID: 15652112 Updated. Review. No abstract available.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists. Dowsett M, et al. Among authors: dixon jm. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s. Clin Cancer Res. 2005. PMID: 15701892 Clinical Trial.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Dowsett M, et al. Among authors: dixon jm. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767642 Clinical Trial.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Smith IE, et al. Among authors: dixon jm. J Clin Oncol. 2005 Aug 1;23(22):5108-16. doi: 10.1200/JCO.2005.04.005. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998903 Clinical Trial.
549 results